talquetamab
janssen
['mmsm', 'monumental-1', 'talquetamab']
congress #eha2022 | , presents updated data on talquetamab, gprc5d and cd3 bispecific antibody, from monumental-1 trial
the most common aes were crs, skin-related aes and dysgeusia. no treatment-related deaths. durable responses deepened over time #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma